SCHEMBL5214345

SCHEMBL5214345

O=C1CCC(N2C=Nc3cc([N+](=O)[O-])ccc3C2)C(=O)N1

nearest known ligand 0.55

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 19/20 0.55
DDB1 Q16531 5/20 0.55
TDP2 O95551 1/20 0.38
IKZF3 Q9UKT9 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1398057 0.89 DDB1 (0.46) CRBNDDB1TDP2
SCHEMBL5216879 0.83 CRBN (0.50) CRBNDDB1IKZF3
SCHEMBL5215782 0.83 CRBN (0.44) CRBNDDB1IKZF3
SCHEMBL5217370 0.83 CRBN (0.56) CRBNDDB1IKZF3
SCHEMBL5162159 0.80 CRBN (0.58) CRBNDDB1IKZF3
SCHEMBL1398083 0.80 DDB1 (0.46) CRBNDDB1TDP2
SCHEMBL5215745 0.78 CRBN (0.50) CRBNDDB1IKZF3
SCHEMBL5217927 0.78 CRBN (0.43) CRBNDDB1IKZF3
SCHEMBL5215113 0.78 CRBN (0.53) CRBNDDB1IKZF3
SCHEMBL19359476 0.77 CRBN (0.57) CRBNDDB1TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456197-B1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 GRUENENTHAL GMBH (DE) 2007-02-28 EP claimed
US-7183274-B2 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2007-02-27 US claimed
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2005-01-27 US claimed
EP-1456197-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2004-09-15 EP claimed
WO-2003053956-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2003-07-03 WO claimed
EP-1456197-B1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 GRUENENTHAL GMBH (DE) 2007-02-28 EP disclosed
US-7183274-B2 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2007-02-27 US disclosed
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2005-01-27 US disclosed
EP-1456197-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2004-09-15 EP disclosed
WO-2003053956-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position DPYD, CYP2D6, DHPS CRBN 4553/4885DDB1 4687/4885TDP2 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.